Company profile
NeoPhore - Cancer Neoantigen Evolution | Neophore
NeoPhore targets the dynamics of cancer neoantigen evolution and makes effective medicines that will become a key part of the next-generation of cancer immunotherapies.
Financial period: 1 Apr 2024 to 31 Mar 2025
Reference milestones and recent Companies House filing stream events.
Next confirmation statement due date
Next accounts due date
TM01 | Transaction MzUzMDAyNDg3NWFkaXF6a2N4
Published 02 Jul 2026 07:49
Last confirmation statement made up date
Last accounts made up date
Company registered at Companies House
1 Jul 2017 to 31 Mar 2020
A new approach to cancer therapy called 'immuno-therapy' has recently emerged that is now providing unheralded responses in certain cancer types. It is based on the concept that as tumours arise through sequential mutations in their genomes, this also creates 'foreign' antigens that can be recognised and attacked by the immune system. However, tumours als...
